Medicare panel backs $93K cancer drug Provenge
Medicare advisers on Wednesday supported the effectiveness of the prostate cancer drug Provenge, an innovative therapy that has prompted questions about the cost of medical care and the government's role in paying for it.
The vote by a 14-member panel of outside experts amounts to a recommendation that Medicare pay for Provenge, which costs $93,000 per patient and extends life an average of four months.
- Hospital Groups Strike Back at Hospital Rating Systems
- 5 Hot Healthcare Ideas from SXSW
- AHIP: Enormity of HIX Challenges Sinks In
- Hospital CEO Turnover Hits Record High
- The Secret to Physician Engagement? It's Not Better Pay
- Another SGR Patch Likely, Lawmaker Says
- Rules to Rein in HIX Narrow Networks Could Drive Away Payers
- How Succession Planning Boosts Employee Retention Rates
- 4 Marketing Tactics for Hospitals on Instagram
- 4 Reasons PCMH Principles Aren't Going Away